enfortumab
astellas,Seagen
['head and neck', 'enfortumab', ' vedo']
join us at 4:30 pm cdt for #rogelcancer researcher paul swiecicki, m.d. and his presentation, enfortumab vedotin in the previously treated advanced head and neck cancer (hnc) cohort of ev-202 in room e451. #asco23 
The University of Michigan Rogel Cancer Center is committed to improving the health and well-being of people with cancer. Part of @umichmedicine. #GoBlue